Dyslipidemia Among Patients With Type 1 Diabetes and Its Associated Factors in Saudi Arabia: An Analytical Cross-Sectional Study

Abdullah A. Alrasheed 1

1. Department of Family and Community Medicine, King Saud University, Riyadh, SAU

Corresponding author: Abdullah A. Alrasheed, abdullahalrasheed03@gmail.com

Abstract

Objectives

The present study was conducted to determine the prevalence of dyslipidemia among patients with type 1 diabetes mellitus (T1DM) and its associated factors in Saudi Arabia.

Methods

An analytical cross-sectional study was conducted to examine patients with T1DM at a tertiary care hospital in Riyadh, Saudi Arabia. The hospital’s electronic medical records (EMRs) and a telephone survey were used to collect data after obtaining institutional approval and informed consent from every patient. The inclusion criteria included age >18 years, T1DM, and follow-up at the tertiary care hospital. The data collected included age, gender, hypertension, glycosylated hemoglobin (HbA1c), body mass index (BMI), diabetes duration, total cholesterol, triglycerides (TG), low-density lipoprotein (LDL), and high-density lipoprotein (HDL).

Results

A total of 234 patients with T1DM were included in the study, which comprised 44.4% men and 55.6% women with an average age of 30.9 ± 9.7 years. Total cholesterol, TG, LDL-C, and HDL-C were 4.6 ± 1.04 mmol/L, 1.1 ± 0.60 mmol/L, 2.6 ± 0.89 mmol/L, and 1.5 ± 0.43 mmol/L, respectively. About 18.4% were hypertensive, and about 51.9% and 50% men and women had dyslipidemia, respectively. Males and HbA1c ≥ 7% showed significant associations with dyslipidemia.

Conclusion

Dyslipidemia is prevalent in patients with T1DM in Saudi Arabia, which warrants the use of solid preventive strategies to limit the risk of cardiovascular disease.

Introduction

Dyslipidemia is an important metabolic disorder that involves persistent abnormally high concentrations of plasma cholesterol and triglycerides (TG) [1]. Dyslipidemia is defined as total cholesterol > 5.17 mmol/L (>200 mg/dL), high low-density lipoprotein-cholesterol (LDL-C) > 3.36 mmol/L (>130 mg/dL), low high-density lipoprotein-cholesterol (HDL-C) < 1.03 mmol/L (<40 mg/dL) for men and < 1.3 mmol/L (<50 mg/dL) for women, and elevated TG > 1.7 mmol/L (>150 mg/dL), or a combination thereof [2]. Dyslipidemia is one of the major but modifiable risk factors for cardiovascular diseases (CVDs) such as myocardial infarction (MI) and stroke. It has been reported that one-third of cases of MI are attributable to high cholesterol [3]. Globally, LDL-C increases both mortality and morbidity, with a burden of 4.32 million deaths and 94.92 million disability-adjusted life years (DALYS) [4].

The prevalence of dyslipidemia is high in patients with T1DM [5], and T1DM increases the risk of CVD by up to 4-10 times [6]. Patients with T1DM show several qualitative and functional atherogenic lipoprotein abnormalities [7] and the prevalence of dyslipidemia among them has been reported to be 72.5%, putting them at increased risk of vascular complications [8].

In addition, it has been reported that patients with T1DM show high LDL-C and low HDL-C [6]. Patients with T1DM are at the risk of the earlier development of atherosclerosis, leading to increased morbidity and mortality [9]. Thus, if T1DM and dyslipidemia are both present, the risk of CVD is even higher. High concentrations of TG, total cholesterol (TC), and low HDL-C have positive associations with poor glycemic control, pushing the risk of diabetic complications even further [9].
The prevalence of dyslipidemia is on the rise worldwide due to Westernized diets, urbanization, poor physical activity, and obesity [10]. A sedentary lifestyle is associated with obesity, elevated TGs, reduced HDL-C, hypertension, and hyperglycemia, resulting in an increased risk of CVD and subsequent mortality and morbidity [10]. LDL-C is the eighth leading risk factor of death worldwide [11], and diabetes is the seventh leading cause [12]. Therefore, evaluation of dyslipidemia, especially among patients with diabetes, is important to enforce preventive strategies, especially among populations at risk for CVD.

In Saudi Arabia, dyslipidemia has been reported in 66.5% of patients with T2DM [13]. However, no literature is available on the prevalence of dyslipidemia in patients with T1DM. Unfortunately, Saudi Arabia stands fifth in the global incidence of T1DM [14]. Thus, Saudi populations with dyslipidemia and diabetes are at high risk of developing cardiovascular events. Therefore, this study was conducted to determine the prevalence of dyslipidemia and its associated factors in Saudi patients with T1DM.

**Materials And Methods**

The relevant data used in this study were extracted from a previous study [15]. An analytical cross-sectional study was conducted to examine patients with T1DM at a tertiary care hospital in Riyadh, Saudi Arabia. After obtaining consent from the Institutional Review Board (IRB: E-20-5530), a list of 900 patients registered from January 2018 to December 2020 in the hospital electronic medical records (EMRs) was accessed, and a telephone survey was conducted to collect data. Informed consent was obtained from every patient before conducting the telephone survey. The inclusion criteria included age >18 years, T1DM, and follow-up at the tertiary care hospital. The exclusion criteria included patients with incomplete data in EMRs and those who had fewer than two visits to the hospital.

A structured interview-based questionnaire was distributed among the patients, and 234 patients were selected for analysis based on the inclusion criteria. The data collected included age, gender, hypertension, glycosylated hemoglobin (HbA1c), basal mass index (BMI), diabetes duration, TC, TG, LDL-C, and HDL-C. Dyslipidemia was defined as total cholesterol ≥ 5.17 mmol/L (≥200 mg/dL), high LDL-C ≥ 3.36 mmol/L (≥130 mg/dL), low HDL-C < 1.03 mmol/L (<40 mg/dL) for men, < 1.3 mmol/L (<50 mg/dL) for women, and elevated TG > 1.7 mmol/L (>150 mg/dL), or a combination thereof [2].

The 26th version of the statistical package of social sciences (SPSS Inc., Chicago, IL, USA) was used to analyze the collected data. Descriptive statistics were used to represent the clinical and background data of the patients. The significance of clinical and background data was assessed via an independent-sample t-test and chi-squared test of independence.

**Results**

The study involved 234 patients with T1DM, including 104 (44.4%) men and 130 (55.6%) women. The mean age of the patients was 30.9 ± 9.7 years, and the mean HbA1c and mean BMI were 8.8 ± 2.0 and 26.4 ± 6.30, respectively. The mean duration of T1DM from the point of diagnosis was 13.7 ± 8.07 years. TC, TG, and LDL-C, HDL-C were 4.6 ± 1.04 mmol/L, 1.1 ± 0.60 mmol/L, 2.6 ± 0.89 mmol/L, and 1.5 ± 0.45 mmol/L, respectively. About 18.4% were hypertensive. Clinical and background characteristics of the patients are given in Table 1.
| Characteristics          | N (%) | M ± SD |
|-------------------------|-------|--------|
| **Sex**                 |       |        |
| Male                    | 104 (44.4) |        |
| Female                  | 130 (55.6) |        |
| **Age**                 | 30.9±9.7 |        |
| **A1C**                 | 8.8±2.0 |        |
| **BMI**                 | 26.4±6.30 |        |
| **Diabetes duration**   | 13.7±8.07 |        |
| **Total cholesterol**   | 4.6±1.04 |        |
| **TG**                  | 1.1±0.60 |        |
| **LDL**                 | 2.6±0.89 |        |
| **HDL**                 | 1.5±0.43 |        |
| **Hypertensive**        |        |        |
| Yes                     | 43 (18.4) |        |
| NO                      | 191 (81.6) |        |

**TABLE 1: Clinical and background characteristics of the participants (n= 234)**

The prevalence of dyslipidemia was 51.9% in men and 50% in women (Table 2). The prevalence of LDL-C dyslipidemia was significantly higher in men than in women (P-value = 0.024, Table 2).

| Categories          | Prevalence | Mean ± SD |
|---------------------|------------|-----------|
| **Dyslipidemia**    |            |           |
| Yes                 | 54 (51.9) | 119 (50.9) |
| No                  | 50 (48.1) | 115 (49.1) |
| **Total cholesterol**|           |           |
| <200 mg/dL          | 71 (68.3) | 165 (70.5) |
| ≥ 200 mg/dL         | 33 (31.7) | 69 (29.5) |
| **Triglyceride**    |            |           |
| <150 mg/dL          | 89 (85.6) | 200 (85.5) |
| ≥150 mg/dL          | 15 (14.40)| 34 (14.5) |
| **LDL-C**           |            |           |
| <130 mg/dL          | 79 (76) | 193 (82.5) |
| ≥130 mg/dL          | 25 (24) | 41 (17.5) |
| **HDL-C (M/W)**     |            |           |
| <40/50 mg/dL        | 24 (23.1) | 52 (22.2) |
| ≥40/50 mg/dL        | 80 (76.9) | 182 (77.8) |

**TABLE 2: Prevalence of dyslipidemia their mean values stratified by gender (n = 234)**

There was no significant difference between men and women in terms of overall dyslipidemia (P-value = 0.79), total cholesterol (P-value = 0.56), and TG (P-value = 0.96). Males had significant dyslipidemia of LDL-C (>130 mmol/L, P-value = 0.018). The patients with HbA1c of >7% had significant dyslipidemia of TC (>200 mg/dL, P-value = 0.023). However, age (P-value = 0.097), gender (P-value = 0.76), HbA1C (P-value = 0.21), BMI (P-value = 0.24), diabetes duration (P-value = 0.074), and hypertension (P-value = 0.11) showed no statistically significant association with overall dyslipidemia. Table 3 represents the factors affecting...
dyslipidemia and lipid components among patients with T1DM, and Table 4 shows the co-occurrence of four dyslipemias in terms of gender.

| Variables  | Categories | Dyslipidemia (n (%)) | Elevated TC (≥200 mg/dL) (n (%)) | Elevated TG (≥150 mg/dL) (n (%)) | High LDL-C (≥130 mg/dL) (n (%)) | Low HDL-C (M/W ≥ 40/50 mg/dL) (n (%)) |
|------------|------------|----------------------|-----------------------------------|-----------------------------------|---------------------------------|----------------------------------------|
| Age        | <25        | 34 (28.6)            | 22 (31.9)                         | 9 (26.5)                          | 13 (31.7)                       | 16 (30.8)                             |
|            | ≥25        | 85 (71.4)            | 47 (68.1)                         | 25 (73.5)                         | 28 (68.3)                       | 36 (69.2)                             |
|            | P-value    | 0.097327             | .361036                           | 0.9625                            | .498456                         | .3449                                 |
| Gender     | Male       | 54 (45.4)            | 33 (47.8)                         | 15 (44.1)                         | 25 (61)                         | 24 (46.2)                             |
|            | Female     | 65 (54.6)            | 36 (52.2)                         | 19 (55.9)                         | 16 (39)                         | 28 (53.8)                             |
|            | P-value    | .769984              | .500818                           | .966913                           | .018997                         | .778492                               |
| A1C        | < 7%       | 13 (10.9)            | 4 (5.8)                           | 3 (8.8)                           | 3 (7.3)                         | 8 (15.4)                              |
|            | ≥ 7%       | 106 (89.1)           | 65 (94.2)                         | 31 (91.2)                         | 38 (92.7)                       | 44 (84.6)                             |
|            | P-value    | 0.212822             | 0.023318                          | 0.73136                           | 0.191989                        | 0.84153                               |
| A1C        | < 8%       | 49 (41.2)            | 25 (36.2)                         | 14 (41.2)                         | 15 (36.6)                       | 23 (44.2)                             |
|            | ≥ 8%       | 70 (58.8)            | 44 (63.8)                         | 20 (58.8)                         | 26 (63.4)                       | 29 (55.8)                             |
|            | P-value    | 0.44887              | 0.142155                          | 0.758881                          | 0.319294                        | 0.91582                               |
| BMI        | < 30       | 91 (76.5)            | 56 (81.2)                         | 24 (70.6)                         | 32 (78)                         | 37 (71.2)                             |
|            | ≥ 30       | 28 (23.5)            | 13 (18.8)                         | 10 (29.4)                         | 9 (22)                          | 15 (28.8)                             |
|            | P-value    | 0.245038             | 0.682052                          | 0.164534                          | 0.801695                        | 0.091516                              |
| BMI        | < 24.9     | 52 (43.7)            | 31 (44.9)                         | 14 (41.2)                         | 18 (43.9)                       | 23 (44.2)                             |
|            | 25 – 29.9  | 37 (31.1)            | 24 (34.8)                         | 10 (29.4)                         | 13 (31.7)                       | 13 (25)                               |
|            | 30 – 34.9  | 19 (16)              | 10 (14.5)                         | 8 (23.5)                          | 7 (17.1)                        | 9 (17.3)                              |
|            | ≥ 35       | 11 (9.2)             | 4 (5.8)                           | 2 (5.9)                           | 3 (7.3)                         | 7 (13.5)                              |
|            | P-value    | 0.341513             | 0.413379                          | 0.248749                          | 0.766612                        | 0.396512                              |
| Diabetes   | < 5 years  | 26 (21.8)            | 17 (24.6)                         | 11 (32.4)                         | 11 (26.8)                       | 11 (21.2)                             |
| duration   | 5 - <10 years | 18 (15.1)          | 9 (13)                            | 4 (11.8)                          | 6 (14.6)                        | 9 (17.3)                              |
|            | ≥ 10 years | 75 (63)              | 43 (62.3)                         | 19 (55.9)                         | 24 (58.5)                       | 32 (61.5)                             |
| Hypertension | Yes        | 27 (22.7)            | 12 (17.4)                         | 10 (29.4)                         | 8 (19.5)                        | 14 (26.9)                             |
|            | No         | 92 (77.3)            | 57 (82.6)                         | 24 (70.6)                         | 33 (80.5)                       | 38 (73.1)                             |
|            | P-value    | 0.074822             | 0.105242                          | 0.071906                          | 0.293708                        | 0.747326                              |

TABLE 3: Factors affecting the prevalence of dyslipidemia and its lipid components (n = 234)
### TABLE 4: Co-occurrence of the four lipid abnormalities stratified by gender (n = 234)

**Abbreviations:** LDL-C: Low-Density Lipoprotein Cholesterol, TC: Total Cholesterol, TG: Triglyceride, HDL-C: High-Density Lipoprotein Cholesterol.

| Lipid abnormalities               | Male      | Female     | Total |
|-----------------------------------|-----------|------------|-------|
| Negative                          | 50 (43.5) | 65 (56.5)  | 115   |
| TC+TG+LDL-C                       | 6 (60)    | 4 (40)     | 10    |
| TC+LDL-C                          | 25 (62.5) | 15 (37.5)  | 40    |
| LDL-C                             | 25 (61)   | 16 (39)    | 41    |
| TG+LDL-C                          | 6 (60)    | 4 (40)     | 10    |
| TG                                | 15 (44.1) | 19 (55.9)  | 34    |
| TG+HDL-C                          | 15 (44.1) | 19 (55.9)  | 34    |
| HDL-C                             | 24 (77.4) | 7 (22.6)   | 31    |
| LDL+HDL-C                         | 25 (61)   | 16 (39)    | 41    |
| TC+TG+LDL-C+HDL-C                 | 6 (60)    | 4 (40)     | 10    |
| TG+HDL-C+HDL-C                    | 6 (60)    | 4 (40)     | 10    |
| TC+TG                             | 7 (43.8)  | 9 (56.3)   | 16    |
| TC+TG+HDL-C                       | 3 (60)    | 2 (40)     | 5     |
| TC                                | 33 (47.8) | 36 (52.2)  | 69    |
| TC+LDL-C+HDL-C                    | 10 (80.9) | 1 (9.1)    | 11    |
| TC+HDL-C                          | 6 (66.7)  | 3 (33.3)   | 9     |

### Discussion

The present cross-sectional study was conducted to determine the prevalence of dyslipidemia among patients with T1DM and its associated factors in a Saudi population. The study revealed that dyslipidemia is prevalent among the population of Saudi Arabia suffering from T1DM, with a marked risk of CVD such as MI and stroke. Male patients had significant dyslipidemia of LDL-C, and patients with HbA1c of ≥7% had significant dyslipidemia of TC.

Type 1 diabetes is an autoimmune disease with a peak incidence in children of age 10-14 years and accounts for 5% of all diabetes cases globally [16]. Dyslipidemia is frequent comorbidity found in diabetic patients with a prevalence of 72.5% or even more [8]. Abed et al. [17] conducted a cross-sectional study and reported a prevalence of dyslipidemia of 64% among 129 young adults with T1DM. Similarly, Mona et al. [18] studied 60 children and adolescents and reported rates of 65% and 28.2% of dyslipidemia in diabetic patients and controls, respectively, where high LDL-C and low HDL-C were the most common forms of dyslipidemia (P < 0.001).

T1DM is a soaring epidemic in Saudi Arabia, affecting 35,000 children. The country is eighth in the world in terms of incidence rate at 33.5 cases per 100,000 individuals [19]. Unfortunately, Alzahrani et al. [20] have reported a rate of 33% of dyslipidemia among Saudi individuals. On the other hand, Alzahib and Altemani [13] have reported dyslipidemia in 66.5% of patients with T2DM. Thus, dyslipidemia is prevalent in Saudi populations with either T1DM or T2DM, although dyslipidemia is relatively less common in patients with T1DM than in those with T2DM. The reason behind this slight difference may be attributed to age since the incidence of dyslipidemia increases with advancing age [21]. The incidence of T1DM peaks at 10-14 years, while the incidence of T2DM peaks at around 55 years of age [22].

In the present study, although overall dyslipidemia was more frequent in men than in women, this difference was not statistically significant. In addition, LDL-C was significantly higher in men than in women. LDL-C is termed as "bad cholesterol," indicating that Saudi men are at higher risk of CVD than women. On the other hand, Homma et al. [8] conducted a retrospective cross-sectional study in Brazil including 239 young patients with T1DM. They reported overall dyslipidemia rates of 81.7% and 61.8% in females and males (P = 0.01), respectively. This difference may be attributed to the retrospective design of the study and the

---

*Alrasheed et al. Cureus 14(2): e21923. DOI 10.7759/cureus.21923*
unknown status of statin therapy. Similarly, Bülut et al. [23] observed more females with overall dyslipidemia as compared to men.

Another important finding in the present study was that patients with HbA1c of >7% had significant dyslipidemia of TC. In support of this result, Abed et al. [17] also reported that higher mean HbA1c was significantly associated with dyslipidemia (P < 0.045). Therefore, men with T1DM and HbA1c of 7% or higher are at high risk of CVD. In this context, timely and strict preventive measures may reduce the risk of adverse cardiovascular events.

The present study did not show any significant association of dyslipidemia with age, BMI, diabetes duration, and the presence or absence of hypertension. In support of the present study, Mona et al. [18] reported that age (P = 0.47) and duration of diabetes (P = 0.29) showed no significant association with dyslipidemia. However, they reported a significant association of BMI (P = 0.024) with dyslipidemia. In contrast, Marcovecchio et al. [24] studied the prevalence of dyslipidemia in 895 T1DM patients and reported significant associations with age (P < 0.001), BMI (P < 0.05), duration of diabetes (P < 0.001), and HbA1c (P < 0.001). Similarly, Soliman and Ibrahim [25] retrospectively studied 806 children and adolescents with T1DM and reported that poor glycemic control was significantly associated with higher components of dyslipidemia (TG, TC, LDL-C), longer diabetes duration, and older age. These differences in the association of dyslipidemia may be explained by the missing data on statin therapy in the present study.

An advantage of this study is that it has reported the prevalence of dyslipidemia in T1DM patients for the first time in Saudi Arabia to the best of our knowledge. The present study has limitations, such as a single-centered design and not including the status of statin therapy of patients.

Conclusions

The prevalence of dyslipidemia is high in Saudi Arabia, indicating a high risk for CVD. Therefore, further studies on the relation of dyslipidemia with T1DM and strict preventive strategies against dyslipidemia are required. Such efforts could reduce the combined risk of dyslipidemia and diabetes in the Saudi population.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Institutional Review Board at King Saud University issued approval E-20-5530. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that there is no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Moor VI, Amougou SN, Ombotto S, Ntone F, Wouamba DE, Nonga BN: Dyslipidemia in patients with a cardiovascular risk and disease at the University Teaching Hospital of Yaoundé, Cameroon. Int J Vasc Med. 2017, 2017:6061306. 10.1155/2017/6061306
2. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation. 2002, 106:3143-421.
3. Mangili L: High prevalence of dyslipidemia in children and adolescents: opportunity for prevention. Arq Bras Cardiol. 2020, 114:57-8. 10.36660/abc.20190761
4. Mattiuzzi C, Sanchis-Gomar F, Lippi G: Worldwide burden of LDL cholesterol: Implications in cardiovascular disease. Nutr Metab Cardiovasc Dis. 2020, 30:241-4. 10.1016/j.numecd.2019.09.008
5. Shah N, Khadilkar A, Gondhalekar K, Khadilkar V: Prevalence of dyslipidemia in Indian children with poorly controlled type 1 diabetes mellitus. Pediatr Diabetes. 2020, 21:987-94. 10.1111/pedi.13063
6. Colom C, Rull A, Sanchez-Quezada IL, Perez A: Cardiovascular disease in type 1 diabetes mellitus: epidemiology and management of cardiovascular risk. J Clin Med. 2021, 10:1798. 10.3390/jcm10081798
7. Vergès B: Dyslipidemia in type 1 diabetes: a masked danger. Trends Endocrinol Metab. 2020, 31:422-34. 10.1016/j.tem.2020.01.015
8. Homma TK, Endo CM, Suhrawashi T, Moriguchi AP, Noronha RM, Monte O, Calliari LE: Dyslipidemia in young patients with type 1 diabetes mellitus. Arch Endocrinol Metab. 2015, 59:215-9. 10.1590/2359-3997000000040
9. Zabeen B, Balsa AM, Islam N, Parveen M, Nahar J, Azad K: Lipid profile in relation to glycemic control in type 1 diabetes children and adolescents in Bangladesh. Indian J Endocrinol Metab. 2018, 22:89-92. 10.4103/ijem.IJEM_217_17
10. Bekele S, Yohannes T, Mohammed AE: Dyslipidemia and associated factors among diabetic patients attending Durame General Hospital in Southern Nations, Nationalities, and People’s Region. Diabetes Metab
11. Pirillo A, Casula M, Olmastoni E, Norata GD, Catapano AL: Global epidemiology of dyslipidaemias. Nat Rev Cardiol. 2021, 18:130-39. 10.1038/s41569-021-00518-8
12. Li S, Wang J, Zhang B, Li X, Liu Y: Diabetes mellitus and cause-specific mortality: a population-based study. Diabetes Metab J. 2019, 43:519-41. 10.4093/dmj.2018.0060
13. Alzahheb RA, Altemani AH: Prevalence and associated factors of dyslipidemia among adults with type 2 diabetes mellitus in Saudi Arabia. Diabetes Metab Syndr Obes. 2020, 13:4035-40. 10.2147/DMSO.S246068
14. Alqaqel AA: Pediatric diabetes in Saudi Arabia: challenges and potential solutions. A review article. Int J Pediatr Adolesc Med. 2019, 6:125-30. 10.1016/j.ijpam.2019.05.008
15. Alrasheed AA, Almammar AM, Alrasheed AA, et al.: The prevalence of hypertension among patients with Type 1 diabetes and its associated factors in Saudi Arabia. Med Sci. 2021, 25:2748-56.
16. DiMeglio LA, Evans-Molina C, Oram RA: Type 1 diabetes. Lancet. 2018, 391:2449-62. 10.1016/S0140-6736(18)31320-5
17. Abed ElBarbera B, Dvorak J, Zhang Y, Beck J, Talsania M: Prevalence of dyslipidemia and factors affecting dyslipidemia in young adults with type 1 diabetes: evaluation of statin prescribing. J Pediatr Endocrinol Metab. 2019, 32:327-34. 10.1515/jpem-2018-0588
18. Mona HM, Saheb SA, Hend SM, Nanees AW: Dyslipidemia in type 1 diabetes mellitus: relation to diabetes duration, glycemic control, body habitus, dietary intake and other epidemiological risk factors. Egypt Pediatr Assoc Gaz. 2015, 63:65-8. 10.1016/j.epag.2015.05.001
19. Robert AA, Al-Dawish A, Mujammami M, Dawish MA: Type 1 diabetes mellitus in Saudi Arabia: a soaring epidemic. Int J Pediatr. 2018, 2018:9408370. 10.1155/2018/9408370
20. Al-Zahrani J, Shuhair MM, Al-Ghamdi S, et al.: The prevalence of hypercholesterolemia and associated risk factors in Al-Kharj population, Saudi Arabia: a cross-sectional survey. BMC Cardiovasc Disord. 2021, 21:22. 10.1186/s12872-020-01824-5
21. Rosada A, Kassner U, Weidemann F, König M, Buchmann N, Steinhagen-Thiessen E, Spira D: Hyperlipidemias in elderly patients: results from the Berlin Aging Study II (BASEII), a cross-sectional study. Lipids Health Dis. 2020, 19:92. 10.1186/s12944-020-01277-9
22. Khan MA, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi I: Epidemiology of type 2 diabetes-global burden of disease and forecasted trends. J Epidemiol Glob Health. 2020, 10:107-11. 10.2991/jegh.k.191028.001
23. Bulut T, Demirel F, Metin A: The prevalence of dyslipidemia and associated factors in children and adolescents with type 1 diabetes. J Pediatr Endocrinol Metabol. 2017, 30:181-7. 10.1515/jpem-2016-0111
24. Marcevecchio ML, Dalton RN, Prevost AT, et al.: Prevalence of abnormal lipid profiles and the relationship with the development of microalbuminuria in adolescents with type 1 diabetes. Diabetes Care. 2009, 32:658-63. 10.2337/dc08-1641
25. Soliman H, Ibrahim A: Prevalence and pattern of dyslipidemia in an Egyptian children and adolescents with type 1 diabetes. Egypt Pediatr Assoc Gaz. 2021, 69:1-7. 10.1186/s45054-021-00067-x